ALXN1850

Phase 3Biologic

AstraZeneca

ALXN1850 is one of 68 biologic programs targeting Hypophosphatasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypophosphatasiaActive, not recruiting

TreatmentActive, not recruiting

PediatricActive, not recruiting

HypophosphatasiaPhase 3

Active, not recruiting

TreatmentPhase 3

Active, not recruiting

PediatricPhase 3

Active, not recruiting

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

ALXN1850

AstraZeneca

Phase 3

1 2

Dexilant

Takeda

Preclinical

2 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 6

Valium

Akero Therapeutics

Preclinical

2 7

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 8

Clomid

Ferring

Preclinical

1 9

Aurlumyn

BBTG International Inc.

Preclinical

1 10

Lotemax

PPharmos

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Pediatric

NCT06079372

Phase 3Active, not recruiting

Hypophosphatasia

NCT06079281

Q3 2028

Phase 3Active, not recruiting

Treatment

NCT06079359

Clinical

Trials by Indication[1]

Hypophosphatasia2 trials

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04980248·15 enrolled

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 Years of Age) and Adult Participants With Hypophosphatasia Who Have Not Previously Been Treated With Asfotase Alfa

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06079281·124 enrolled

Treatment1 trial

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06079359·30 enrolled

Pediatric1 trial

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06079372·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ALXN1850. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALXN1850 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALXN1850. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

ALXN1850

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Trials by Indication[1]

Hypophosphatasia2 trials

Treatment1 trial

Pediatric1 trial

References

Drug Info

Quick Facts

Related News